KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Other Accumulated Expenses: 2018-2024

  • Adaptive Biotechnologies' Other Accumulated Expenses rose 8.78% to $830,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $830,000, marking a year-over-year increase of 8.78%. This contributed to the annual value of $830,000 for FY2024, which is 8.78% up from last year.
  • As of Q4 2024, Adaptive Biotechnologies' Other Accumulated Expenses stood at $830,000, which was up 8.78% from $763,000 recorded in Q4 2023.
  • In the past 5 years, Adaptive Biotechnologies' Other Accumulated Expenses ranged from a high of $1.9 million in Q4 2020 and a low of $763,000 during Q4 2023.
  • Over the past 3 years, Adaptive Biotechnologies' median Other Accumulated Expenses value was $830,000 (recorded in 2024), while the average stood at $1.1 million.
  • In the last 5 years, Adaptive Biotechnologies' Other Accumulated Expenses soared by 238.31% in 2020 and then slumped by 53.90% in 2023.
  • Quarterly analysis of 5 years shows Adaptive Biotechnologies' Other Accumulated Expenses stood at $1.9 million in 2020, then crashed by 44.50% to $1.0 million in 2021, then surged by 58.52% to $1.7 million in 2022, then slumped by 53.90% to $763,000 in 2023, then rose by 8.78% to $830,000 in 2024.
  • Its Other Accumulated Expenses stands at $830,000 for Q4 2024, versus $763,000 for Q4 2023 and $1.7 million for Q4 2022.